Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma
Laura Escudero, Anna Llort, Alexandra Arias, Ander Díaz‐Navarro, Francisco Martínez‐Ricarte, Carlota Rubio-Pérez, Regina Mayor, Ginevra Caratù, Elena Martínez‐Sáez, Élida Vázquez‐Méndez, Iván Lesende‐Rodriguez, Raquel Hladun, Luis Gros, Santiago Ramón y Cajal, María A. Poca, Xosé S. Puente, Juan Sahuquillo, Soledad Gallego, Joan Seoane
Abstract
The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects.